NOBEX Corporation
!S!WCRTESTINPUT000000!E!
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NOBEX Corporation
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising
China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections.
Oruka Aiming At AbbVie, UCB In Psoriatic Indications
The third Paragon spinout, going public in a reverse-merger with ARCA, announced a concurrent $275m financing to help it develop optimized biologics as potential standards of care in psoriasis and psoriatic arthritis.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice